Drug & intervention
inavolisib
RxCUI 2695422
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
17 shownA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerNCT07405801 · 2026-04-07
RECRUITINGA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerNCT07287150 · 2026-03-11
RECRUITINGTo Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerNCT07368998 · 2026-02-18
RECRUITINGA Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast CancerNCT07347600 · 2026-01-21
RECRUITINGA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerNCT07054190 · 2025-09-09
RECRUITINGA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerNCT06790693 · 2025-04-09
RECRUITINGA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerNCT05894239 · 2023-09-08
RECRUITINGGenomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)NCT05332561 · 2023-06-29
RECRUITINGA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyNCT05646862 · 2023-06-07
RECRUITINGNeoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerNCT05306041 · 2023-01-02
RECRUITINGA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerNCT04802759 · 2021-06-22
RECRUITINGA Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesNCT07748208 · 2026-10-30
NOT_YET_RECRUITINGA PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationNCT05708235 · 2024-04-01
ACTIVE_NOT_RECRUITINGCirculating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast CancerNCT04849364 · 2021-08-24
TERMINATEDA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationNCT04449874 · 2020-07-29
ACTIVE_NOT_RECRUITINGA Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerNCT04191499 · 2020-01-29
ACTIVE_NOT_RECRUITINGTo Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerNCT03006172 · 2016-12-13
ACTIVE_NOT_RECRUITINGConditions being studied
Breast Cancer10Metastatic Breast Cancer2Advanced Solid Tumors1Colorectal Cancer1Diabetes Type II1Early-stage Breast Cancer1HER2-positive Breast Cancer1Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer1Locally Advanced Breast Cancer1Metastatic Castration-Resistant Prostate Cancer1Non-Small Cell Lung Cancer1Solid Tumor1Triple Negative Breast Cancer1
Research locations
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.